About 75% of new human infections worldwide originate from animals. However, currently available drugs for the treatment of vector-borne diseases in humans and animals are few, have limited efficacy or toxicity, and are resource-limited. In addition, there is growing concern about the environmental impacts of pharmaceutical use and production. As drug development processes for humans and animals are developed separately, collaboration between experts in different fields is essential to develop new drugs in a more sustainable manner.
Project funding:
EU COST Programme
Project results:
OneHealthdrugs aims to coordinate the development of new drugs for vector-borne diseases in humans and animals, while respecting the principles of efficacy appropriate for both organisms, and improving their quality and application technologies. COST activities provide an ideal platform to bring together drug research and development experts from the fields of chemistry, biology, medicine, veterinary medicine, and earth sciences, thereby combining the knowledge and resources of small and medium-sized enterprises, industry, and government institutions to create synergies.
Period of project implementation: 2024-03-15 - 2026-10-23
Project partners: Albania, Belgium, Croatia, Cyprus, Georgia, Israel, Latvia, Malta, Poland, Slovakia, Slovenia, Sweden, Switzerland, Bosnia and Herzegovina, Bulgaria, Czech Republic, Denmark, Estonia, Suomija, France, Germany, Greece, Iceland, Italy, Lithuania, North Macedonia, Portugal, Romania, Serbia, Spain, Turkey, United Kingdom
